-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Overweight on Akebia Therapeutics, Lowers Price Target to $2

Benzinga·11/16/2026 13:05:31
Piper Sandler analyst Allison Bratzel maintains Akebia Therapeutics (NASDAQ:AKBA) with a Overweight and lowers the price target from $4 to $2.